Latest Coles News

Pure Foods Tasmania reports a significant operational turnaround in 1H FY26, driven by strategic cost reductions, expanded distribution deals with major retailers, and the acquisition of premium ice cream brand Elato.

Pure Foods Tasmania reports a $6.85 million half-year loss, driven by a strategic operational reset and loan covenant breach, while showing signs of stabilisation and margin improvement.

Coles Group reported a 2.5% revenue increase to $23.7 billion for the half year ended January 2026, driven by strong supermarket sales, but earnings were weighed down by a $235 million provision linked to a Fair Work Ombudsman ruling. The company declared a fully franked interim dividend of 41 cents per share.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

MyEco Group has reported a 38% improvement in profit before tax and a 51% rise in normalised EBITDA for the first half of FY26, driven by operational restructuring and targeted sales growth. The company’s refreshed leadership team and strategic priorities set the stage for further expansion in sustainable packaging markets.

Charter Hall Long WALE REIT reported a solid first half for FY26, with a 2% rise in operating earnings per security and a $139 million uplift in property valuations, underpinned by a diversified portfolio and strong tenant demand.

Charter Hall Long WALE REIT has reported steady earnings growth and a significant portfolio valuation uplift in its half-year results, reaffirming its FY26 guidance despite trading at a notable discount to net tangible assets.

Charter Hall Long WALE REIT reported a striking 209% surge in statutory profit for H1 2026, alongside a modest increase in distributions, underpinned by strategic acquisitions and a shift in accounting standards.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

Farm Pride Foods reported a robust net cash inflow of $32.56 million for the December quarter despite mounting pricing pressures and increased industry egg volumes. The company is doubling down on capital expenditure and operational improvements to sustain efficiency.

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.